

December 24, 2025

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir

Reg: Disclosure under Regulation 30 of SEBI Listing Regulations

Sub: Completion of US-FDA Inspection at the Formulations Facility of Strides Pharma Inc., USA, a step-down wholly owned subsidiary of the Company

We hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Formulations Facility of Strides Pharma Inc. USA (SPI), a step-down wholly owned subsidiary of the Company, at Chestnut Ridge, New York, USA during the period December 17, 2025 to December 23, 2025.

At the conclusion of the inspection, the U.S. FDA has issued a Form 483 with four observations. These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products. SPI will respond to these observations comprehensively to FDA within the stipulated time and is confident of addressing all the observations to the satisfaction of USFDA.

We will keep the stock exchanges informed if there is any further update in this matter.

Please take the above information on record.

Thanks & Regards,

For **Strides Pharma Science Limited**,

-Sd-

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

Tel: +91-80-6784 0000 **Fax:** +91 80 6784 0700

Regd Off: 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

Tel: +91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com